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Abstract: GNAS1 codes for a part of the a-stimulatory subunit (Gsa) of the G protein. Mutation of GNAS1 
has been frequently found in myxoid soft tissues, however, in gastrointestinal tumors, little is known about 
the mutation status of GNAS1. The aim of the study was to analyze the occurrence of GNAS1 mutations in 
different gastrointestinal, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and colorectal tumors. 
Mutation status of GNAS1 exon 8 was analyzed in one hundred thirty-five formalin-fixed, paraffin-embedded 
(FFPE) gastrointestinal tumor samples including 45 tubular-villous adenomas, 11 tubular adenomas, 6 villous 
adenomas, 10 hyperplastic gastric polyps, 31 GEP-NETs and 32 colorectal adenocarcinomas by using polymerase 
chain reaction (PCR) and direct sequencing. Five GNAS1 mutations were found in 2 tubular-villous adenomas, 
2 villous adenomas and 1 colorectal adenocarcinoma. No mutations were detected in the tubular adenomas, the 
hyperplastic gastric polyps or GEP-NETs. GNAS1 mutation is not a frequent molecular event in GEP-NETs or 
hyperplastic gastric polyps. The study confirms the presence of GNAS1 mutations in colon tumors with villous 
differentiation. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 2, 90–95)
Key words: GNAS1 mutations; gastric cancer; intestinal tumors; CRC; GEP-NETs 
Introduction
Cancer is worldwide and especially in more industria-
lized nations a major reason for hospitalization and 
treatment. In 2008, there were 447 000 new cases of 
colorectal cancer in the European Union [1]. About 
65% of all new cases occur in high-income countries. 
Behavioral risk factors including diet, alcohol intake 
and physical inactivity account for a large proportion 
of cases. In Europe, colorectal cancer (CRC) is the 
second most common cause of cancer death in both 
men and women. It is the second most common form 
of cancer in women, after breast cancer, and the 
third most common in men, after lung and prostate 
cancer [1]. Although the incidence of gastric cancer is 
decreasing, there were still 159 900 new cases in Eu-
rope in 2006, and about 118 200 deaths, representing 
the fifth highest incidence and fourth highest cause 
of cancer-related death [2]. To achieve a reduced 
mortality of gastrointestinal cancer, a better under-
standing of the molecular mechanisms underlying 
carcinogenesis is essential which eventually will lead 
to early diagnosis of the disease.
The GNAS1 gene is located on chromosome 
20q13.3. It has 13 exons and can undergo alternative 
splicing [3, 4]. GNAS1 codes for the a-stimulatory 
subunit (Gsa) of heterotrimeric G proteins. Gsa 
activates the adenylyl cyclase which then catalyzes 
cyclic adenosine monophosphate (cAMP) produc-
tion and can thereby regulate downstream signaling 
pathways [6]. As a vital parameter in cellular signaling 
Gsa is ubiquitously found [7]. Different diseases are 
described with gain-of-function and loss-of-function 
mutations such as McCune-Albright-Syndrome, 
a disease which combines café-au-lait spots, polyostotic 
fibrous dysplasia and endocrinopathies [8], fibrous 
dysplasia itself [9] or endocrinological diseases like 
pseudohypoparathyroidism [10] with various muta-
tion hotspots [11]. How imprinting mechanism of this 
gene leads to different diseases partly depending on 
parent’s gender, is not totally understood [5]. Because 
of the widespread occurrence of G-protein-coupled 
receptors mutations the gene could in principle be 
involved in a large number of different tumor types. 
And indeed, it was shown that GNAS1 mutation could 
be found in different neoplasia throughout the whole 
body ranging from pituitary gland tumors [12] over 
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pancreatic intraductal papillary mucinous neoplasm 
(IPMN) [13, 14], low-grade appendiceal mucinous 
neoplasia [15], villous adenomas of the colorec-
tum [16] to colorectal carcinoma [17]. However, the 
mutation status of GNAS1 in gastrointestinal cancer 
has not yet been well investigated. So far only a hand-
ful of publications addressed this issue. Therefore in 
our study we focused on mutation analysis of GNAS1 
in different neoplasia of the digestive tract. 
Material and methods
Tumor samples. Altogether 135 gastrointestinal tumor 
samples from different entities were included in our study 
(Table 1). Among them, 45 were tubular-villous adenomas, 
11 tubular adenomas, both of them ranging from low to high 
grade, 6 villous adenomas, a rare tumor type, 10 hyperplastic 
gastric polyps, 31 gastroenteropancreatic neuroendocrine 
tumors (GEP-NETs) and 32 colorectal adenocarcinomas. 
The tubular-villous adenomas were collected throughout 
the whole gastrointestinal tract and were found in follo-
wing regions: sigmoid colon — 13, colon not otherwise 
specified — 11, descending colon — 6, cecum — 5, rectum 
— 4, transverse colon — 3, and ascending colon — 3. All 
entities described above were removed endoscopically or 
surgically, and were fixed in formalin and embedded in 
paraffin (FFPE). The GEP-NET collective represented 
a subgroup from a recently published series [18]. The grading 
for the tumor samples was defined according to the WHO 
classification of tumors of the digestive system [19]. The 
GEP-NETs grading was performed according to Capella 
et. al [20]. All samples were retrieved from the collection of 
the Institute of Pathology of the Jena University Hospital; 
the GEP-NETs from 1995 to 2008 and all the other samples 
from 2010 to 2012. 
Genomic DNA isolation, PCR product purification. Geno-
mic DNA was isolated from the 135 FFPE tumor samples by 
using a QiAmp® DNA Mini Kit (Qiagen, Hilden, Germany) 
following the guidelines of the manufacturer.
The primer pair: 5´-CTCTTTCCAAACTACTCCA-
GACC-3´ (sense) and 5´-AGCTGGTTATTCCAGAGG-
GACT-3´ (antisense) was used for the PCR amplification 
of GNAS1. PeqSTAR 96 Universal Gradient PCR thermo-
cycler has been used for PCR amplification and PeqGold 
Hot Taq DNA polymerase (Peqlab Biotechnology GmbH, 
Erlangen, Germany) was applied. PCR was performed in a 
50 µl volume (50–100 ng genomic DNA, 2.0 mM dNTPs and 
10 pmol of primer pair) under the following conditions: 94°C 
1 min, 56°C 45 s, 72°C 45 s, for 40 cycles after an initial dena-
turation at 95°C for 15 min and a final elongation at 72°C for 
7 min. In each PCR run, positive and negative controls were 
included. The expected size of the GNAS1 product is 252-bp. 
All PCR products were visualized on a 1.5% agarose. PCR 
products were purified by using a DNA Clean&Concentra-
tor™ 5-KIT (Zymo Research Europe, Freiburg Germany) 
according to the manufacturer’s instructions. One hundred 
nanogram (100 ng) of purified PCR products were applied 
for direct sequencing by capillary electrophoresis (LGC 
Genomics, Berlin, Germany).
Results
Of all 135 samples examined, we found that only 5 
cases (3.7%) showed GNAS1 mutations (Table 1). In 
adenomas, 4 out of 62 (6.45%) were mutated. One of 
the mutated adenoma could not be assigned to a speci-
fic region of the colon, whereas all other 3 were found 
in the rectum. The mutation pattern of all GNAS1 
positive adenomas was a change from Arginine to 
Histidine (R201H; CGT > CAT) (Figure 1). Two 
of them were diagnosed as tubular-villous low grade 
adenomas and 2 were villous high grade adenomas, 
one with severe and one with moderate dysplasia. Out 
of the 32 colorectal carcinomas, only one positive case 
(3.13%) was identified. It consisted of the recurrence 
of a mucinous rectal adenocarcinoma (rpT3, rpN0 
(0/5), L0, V0, Pn0, G3, R0). In contrast to the muta-
tions of adenomas, the nucleotide exchange resulted 
in the substitution of Arginine to Cysteine (R201C; 
Table 1. Study collective and experimental results
Entity Number of samples Age Mutations found Kind of mutation
Tubular-villous adenoma 45
Mean 76; range 47–85
2 R 201 H
Tubular adenoma 11 No
Villous adenoma 6 2 R 201 H
Hyperplastic gastric polyps 10 Mean 72; range 49–85 No
GEP-NET’s 31 Mean 56; range 19–87 No
Colorectal adenocarcinoma 32 Mean 77; range 58–85 1 R 201 C
All 135 5
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Forward: exchange of  
guanine against adenine
Reverse: exchange of  
cytosine against thymine
Forward: exchange of  
cytosine against thymine
Reverse: exchange of  
guanine against adenine
Figure 1. Sequence analysis of GNAS1 R201H mutation in a villous adenoma
Figure 2. Sequence analysis of GNAS1 R201C of the colorectal carcinoma
CGT > TGT) (Figure 2). The carcinoma harbored an 
additional KRAS mutation (G13D; GGC > GAC). 
The histological analysis of the GNAS1-mutated 
tumors revealed no peculiar patterns compared to 
the non-mutated cases (Figure 3). 
No GNAS1 mutation was found in 10 hyperplastic 
gastric polyps and 31 GEP-NETs.
Discussion
Many signaling pathways are connected with stimu-
latory G proteins. In particular, G protein-coupled 
receptors are the most common receptors which exert 
their function through nucleotide exchange on hete-
rotrimeric G proteins [21]. These receptors undergo 
an exchange of GTP for GDP on the Gsa-subunit 
initiating downstream signaling [22]. Mutations in 
Gsa itself, but also mutations in the binding pocket 
of G protein-coupled receptors, can affect their 
downstream function [23]. Being embedded with its 
seven transmembrane domains [24] in the double 
lipid layer of a cell, a G protein-coupled receptor 
transfers information from outside to the inside by the 
heterotrimeric G protein and in particular by its GTP
-bound alpha subunit. GNAS1 therefore represents a 
fundamental link to stimulate the cell in order to carry 
out its proper function. False stimulation or missing 
input leaves the cell without vital information or may 
initiate autonomous growth. Generally, mutation can 
cause an uninhibited activation [25] or a loss of func-
93GNAS1 in gastrointestinal tumors
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0011
www.fhc.viamedica.pl
tion [5]. Tissues with high cell turnover like epidermis 
or epithelium of gastrointestinal tract are especially 
vulnerable for acquiring mutations. It was proved 
long ago that RAS, a small G protein, is frequently 
mutated in colorectal cancer. GNAS1, however, was 
only recently identified to be mutated in a subset of 
colon neoplasia, i.e. villous adenoma [16]. Therefore, 
we decided to assess the most frequent mutation of 
GNAS1 gene by analyzing the FFPE samples of dif-
ferent subsets of gastrointestinal tumors. 
In our study, among 45 tubular-villous adenomas, 
2 cases showed GNAS1 mutations (4.44%), which 
is in good agreement with the data from Yamada 
et al., who tested 35 tubular-villous adenomas and 
found only in one case (3%) a GNAS1 mutation [16]. 
It indicates the possibility that GNAS1 mutations 
could be a factor in adenoma development. GNAS1 
R201H and R201C are the most frequently missense 
mutations found in different non-cancer and cancer 
diseases [9, 26]. Interestingly Yamada et al. found 
that 20 out of 24 (83%) villous adenomas presented 
GNAS1 mutations [16]. We could prove two GNAS1 
mutation out of 6 villous adenomas (33.33%). This 
discrepancy between findings may be explained by 
a different racial background between Japanese and 
Caucasian populations. In fact, a very recent Japanese 
study of 12 villous adenomas in association with colon 
adenocarcinoma confirmed the high incidence since 
GNAS1 mutations were detected in 9 cases (75%). 
Interestingly, the GNAS1 mutations were shared in 
only 3 of the 12 adenocarcinomas (25%) of which 
11 also harbored KRAS mutations [27]. It should be 
mentioned, however, that this study came from the 
same group that initially reported GNAS1 mutation 
in villous adenoma. Unfortunately, to our knowledge 
there are no independent reports from other groups 
confirming the high incidence of GNAS1 mutations 
in villous adenoma. Still, the data implicates that there 
may be a connection between a villous differentiation 
and the GNAS1 mutation in codon 201. The fact that 
also tubular-villous adenomas were mutated, suggests 
that even a small villous component raises the possibility 
of carrying a GNAS1 mutation. In contrast pure tubular 
adenomas showed no mutation, which corroborates the 
up to now published data [16]. Thus, it seems that there 
is no or only a very small relationship between tubular 
differentiation in colorectal adenoma and the GNAS1 
mutation. This should be evaluated in further studies, 
with discrimination between the villous and tubular 
components and separate testing of the GNAS1 locus.
We found only one GNAS1 mutation in 32 tested 
colorectal adenocarcinomas. This is in concordance 
with the data from other groups regarding GNAS1 
analysis. I.e., Yamada et al. found 2 mutations in 76 
(3%) colorectal adenocarcinomas [16]. Because of 
the above mentioned possible connection between 
villous differentiation in adenoma and the GNAS1 
mutation, we wanted to examine if there was a 
similar villous component in our GNAS1 mutation 
positive tested CRC. However, our assumption co-
uld not be confirmed, because no remarkable villous 
differentiations were found in this specific GNAS1 
positive CRC. Furthermore, there was no noticeable 
distinction in the histological appearance between 
the one mutated sample and the other 31 colorectal 
adenocarcinomas. Further studies of CRC focusing 
on the histological appearance and their possible 
GNAS1 mutation should be performed to classify the 
importance of this mutation in the development of 
colorectal adenocarcinoma. The recent study by Se-
kine et al. might indicate that the mutation is relevant 
for tumor initiation but dispensable for malignant 
Figure 3. Representative histological images of two adenomas with GNAS R201H mutations in routine hematoxylin-eosin 
staining (× 200 magnification)
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tumor progression. It confirms our observation of the 
potential coincidence with a KRAS mutation [27]. 
Another recent study of 428 colon adenocarcinoma 
reported a rather low GNAS1 mutation rate of 2.3% 
and also a coincidence with KRAS mutations. In 
addition, a correlation with right-sided location was 
reported, however, this finding does not correlate 
with our case which consisted of the recurrence of 
a rectal adenocarcinoma [28]. In addition, it may be 
interesting to compare the mutation status with the 
immunohistochemical expression pattern of colon 
tumors, e.g. markers like CDX2, desmocollin 1–3, 
PITXI [29] or the MSS/MSI phenotype. 
Similarly to other studies [16] we did not find 
GNAS1 mutations in hyperplastic gastric polyps. 
Thus, GNAS1 mutation seems to be a rare molecular 
event in hyperplastic polyps. The analysis was inspired 
by recent studies showing GNAS1 mutations in pylo-
ric gland adenomas [30, 31]. Our results suggest that 
distinct genes and pathways are affected in different 
gastric tumor entities. 
GEP-NETs are neuroendocrine tumors with a rising 
incidence and also represent the most common NETs 
[32]. Plöckinger et al. suggested surgery as the only 
therapeutic option for patients with GEP-NETs [33] 
and despite severe pharmacologic tests it is still the 
only option currently [34], although radionuclide the-
rapy showed a certain constricted value [34]. Patients 
with GEP-NETs have a very heterogeneous prognosis, 
ranging from an overall five-year-survival from 100% 
to lower than 10% depending on the location of tumor 
and its biological aggressiveness [35]. Therefore, it is 
particularly important to identify biomarkers and bet-
ter understand biology of these tumors with regard to 
early diagnosis and treatment. Since we did not find any 
GNAS1 mutation in 31 GEP-NETs, it may be assumed 
that this mutation is rarely involved in the development 
of this kind of tumors. Our findings contrast with re-
ports which showed a detectable frequency of GNAS1 
mutation in other neuroendocrine tumors, for example 
40% GH-secreting pituitary tumors presented GNAS1 
mutations [36] and toxic thyroid adenomas — 4.71% 
GNAS1 mutations [37]. The mutational spectrum of 
GNAS1 seems also to be different in patients with 
pseudohypoparathyroidism [38]. 
In summary, GNAS1 exon 8 mutations seem to be 
rare events in gastrointestinal tumors. We confirmed 
that GNAS1 mutations may occur in tubular-villous 
adenoma and villous adenoma. GNAS1 mutations may 
be particularly important for epithelial colon tumors 
with villous differentiation, however, they occur very 
rarely in colorectal adenocarcinoma. Moreover, GEP- 
-NETs and hyperplastic polyps of the stomach seem not 
to be connected to genetic mutation of GNAS1 exon 8.
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